Skip to content

Claude Code / MCP·Privacy Policy

AlphaRose Therapeutics — Pitch

Back to directory

AlphaRose Therapeutics

AlphaRose unlocks precision medicines for patients without a cure

pitch_v1_import

AustinFounded 2023

Genetics & GenomicsBiotech

Capital FactoryAll Access Fund 2024

🟢 Raising seed — $3.0M target

Activity

Jan 2026

Oversubscribed CLN + increased by $1M

We are oversubscribed on the CLN, and raised it to $3M with <1M currently available. (Closes Feb 2026)

See something off about this company?

CM

Casey McPherson

Jan 20, 2026

A quick update: \r\n\r\nIt's been nonstop at AlphaRose! We just came back from JPM with some significant investor conversations, and heading to Saudi Arabia at the end of Jan for more. Our valuation is rising, and our team is growing! We have a $3M CLN open that should close soon, with $2.1M already filled. We're open to investors that want to make an impact in patients lives with genetic medicine, changing the way that we think about how we make and deploy the medicine of the future for patients. \r\n\r\n- We acquired RareLabs, a personalized genetic medicine lab here in Austin, Tx with an achievable goal of $1.2M in revenue in 2026. We've created 8 new treatments in the lab, which two patients are already on and seeing results. \r\n- We're in multiple conversations with institutions for AlphaRose to acquire clinical stage assets for our Rare HoldCo model. (these most likely will yield a 200-600% return at peak AR, currently only available to our company investors) \r\n\r\nLastly, we're very excited about the MHRA and FDA guidances, that are doing what we've been preparing all along - approving the process of making medicines at scale. Check out this latest article from the economist, hot of the press: https://www.economist.com/science-and-technology/2026/01/19/treatment-of-a-teenager-with-an-ultra-rare-condition-is-a-medical-milestone\r\n\r\nIf you're interested in the future of medicine. Now is the time. The Note is almost filled, the minimum investment currently is $50k, and comes with warrants. After this note closes in Feb 2026, we enter our Series Seed Round with a significantly higher valuation, and terms. Reach out about the opportunity if it seems like a potential fit. \r\n\r\nPatients are waiting,\r\n\r\nCasey McPherson & AlphaRose Team

CM

Casey McPherson

Oct 8, 2025

AlphaRose has built significant value over this last quarter, with 5B+ in potential revenue waiting to be unlocked. Our team is very excited about the incredible opportunities in front of us. \r\n\r\nTo that end, we are announcing a $2m Convertible Note that just opened, Oct 1st - Nov 30th for select investors. The note is filling fast. Please reach out to me immediately if you have interest. ([email protected] / 512.940.4164)\r\n\r\nSome significant markers: \r\n- We are currently now advancing 5 genetic treatments in the pipeline. ($XB in potential annual revenue) \r\n- We are continuing to develop our two proprietary RNA technologies (abcDNA and SOT Caller) poised for large licensing deals as early as 2026. (see Merck and Skyhawk as an example) \r\n- We are in multiple discussions with potential partners in biotech, venture, and healthcare systems. \r\n- We closed our Reg CF Round Sept 30th with $1.6M in additional investment.\r\n- We have two non-dilutive grants we're working on totaling over $50M in potential capital.\r\n- We have board approval to acquire RareLabs, a private genetic treatment lab in Austin, Tx, bringing in $1M in AR.\r\n\r\nAlphaRose is poised to be a revenue generating company in 2026 and beyond, and we are excited about the impact we will be making for patients with genetic diseases for generations to come! \r\n\r\nFor more info on the note and a company update Click here: https://alpharose.info/introdeckcln2\r\n\r\nSincerely, \r\n\r\nCasey McPherson and the AlphaRose Team \r\n

Oct 2025

Opened Convertible Note for 2M (Oct 1st - Nov 30th)

AlphaRose opened their second convertible note with favorable terms, with internal investors priority, from Oct 1st - Nov 30th 2025.

Jun 2025

Sot Caller (epigenetic platform)

We filed a provisional patent for our new epigenetic platform, ”Sot Caller.” This technology has the potential of changing gene expression throughout the human body. In addition to new therapies we create with it, similliar technologies have produced licensing deals in the xB's. Our plan is to develop this modality with new treatments, and once reach sufficient data, we will be poised to execute partnerships with biotech and pharma.

Aboutpitch_v1_import

AlphaRose makes genetic medicines faster and more affordably, giving potential access to millions of suffering patients unaddressable by pharma. Using their vertically integrated system, AlphaRose plans to make hundreds of treatments for less time and money than pharma spends to make one. Think Star Trek of genetic medicines. The company is co-founded by executives from the most successful rare disease company to date, Genzyme Corporation, and collectively the team has commercialized over 20 rare disease products globally. The companies' lead product, "Rosiphersen," is slated for clinical trials in early 2026. For the first time in history, families no longer have to rely on the pharmaceutical industry to decide whether their loved ones receive treatment.

Problempitch_v1_import

400 million people suffer from 10,000+ rare genetic diseases, and most are ultra rare. Currently, we have the technology to treat thousand of these diseases, but we don't have the business models to do it sustainably. Personalized genetic medicine is coming, but the business model, AI, robotics, and scalable systems must be built to open up this multi trillion dollar market. AlphaRose is building this system.

Tractionpitch_v1_import

Alpha Rose has raised $2.6m
AlphaRose in-licensed Rosiphersen which is slated for clinical trials in 2026, with an expected peak annual revenue of $700m.
They have 4 additional genetic treatments in the pipeline, with $XB in AR potential.
The AI platform they are developing has already identified 300+ diseases that are potentially amenable to their technology platform.
AlphaRose has acquired a new ASO technology company, "Alpha Anomeric", giving it the ability to out license, and co-develop treatments with big pharma.
AlphaRose filed a patent for a new platform called "Sot Caller," targeting epigenetic expression. Also with the ability to out license, develop, and co-develop treatments with big pharma.
New FDA regulations as of Sept 2025 have created a favorable pathway for the diseases that AlphaRose is targeting
AlphaRose is in multiple discussions with potential partners, and pursuing non-dilutive funding opportunities.

Team

CM

Casey McPherson

founder

Links

Website LinkedIn Facebook

Share this profile

Sign in to see contact details

Pitch deck

AlphaRose Intro Deck Q3 | 2025.pdf

17.4 MB · Uploaded Apr 24, 2026

This pitch deck is for investors.

Sign in to view →

This section requires investor access

Apply for investor access

Video